ArticleWorld journal of psychiatry2025
Computerized cognitive behavioral therapy with sertraline in schizophrenia with depressive episodes: A 12-week randomized controlled trial.
Article in World journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antidepressant Augmentation of Antipsychotic Treatment in Schizophrenia: A Narrative Review.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia is commonly associated with comorbid depression, which exacerbates cognitive impairments and negatively impacts quality of life. Despite the high prevalence and burden of these comorbidities, effective treatment options, particularly for cognitive dysfunction, remain limited.
aimTo evaluate the efficacy of computerized cognitive behavioral therapy (CCBT) with sertraline
methodsIn this single-center, randomized controlled trial, 68 adults [mean age (SD) = 36.5 (10.0), 57.4% male] with schizophrenia and depressive symptoms were randomly assigned to receive either CCBT with sertraline or sertraline monotherapy during a 4-week hospitalization. The CCBT intervention involved 45-60-minute sessions twice weekly for four weeks. Outcomes included comparisons of depressive symptoms (Calgary depression scale for schizophrenia), cognitive function [MATRICS consensus cognitive battery (MCCB)], and quality of life (36-item short form survey) between the groups.
resultsThe experimental group showed greater improvements in depressive symptoms at 4, 8, and 12 weeks compared to the controls, with the most notable difference at 12 weeks [mean difference (MD) = -1.7;
conclusionCCBT with sertraline was more effective than sertraline monotherapy for patients with schizophrenia and depressive episodes, supporting its use as an adjunctive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.